MBX Biosciences (MBX) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for MBX Biosciences (NASDAQ: MBX):

• 7/29/2026 – MBX Biosciences had its price target raised by Mizuho from $57.00 to $91.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – MBX Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/23/2026 – MBX Biosciences had its “buy” rating reaffirmed by UBS Group AG. They now have a $90.00 price target on the stock.
• 7/20/2026 – MBX Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – MBX Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/12/2026 – MBX Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.